How did Foundayo's second-week prescription numbers compare to oral Wegovy's, and what did analysts say about that performance?

Foundayo was prescribed 3,707 times in its second week (ended April 17), up from 1,390 in its debut week, while oral Wegovy achieved 18,410 prescriptions in its second week and 3,071 in its first four days — meaning Foundayo’s second-week volume was only about 20% of oral Wegovy’s first full week. Analysts described Foundayo’s uptake as 'modest' (Truist), 'likely to be received negatively' (RBC), and falling short of the ~8,000 prescriptions they had hoped for to maintain relative momentum against Wegovy (Deutsche Bank).

What factors did analysts cite to explain Foundayo's slower initial prescription ramp compared to oral Wegovy?

Analysts attributed Foundayo’s slower ramp to Wegovy’s first-mover advantage in time-to-market and brand recognition, with J.P. Morgan noting the difference was 'not surprising' given those factors; Lilly itself cautioned that early weekly figures were incomplete, might not reflect all pharmacy partners, and should be 'best interpreted over time rather than as a complete count.'

Eli Lilly's Obesity Pill Records Modest Second Week as Battle with Novo Nordisk Intensifies

Apr 24, 2026

Eli Lilly's new oral obesity drug Foundayo recorded 3,707 U.S. prescriptions in its second week, falling short of analyst expectations compared to competitor Novo Nordisk's Wegovy. Shares dropped nearly 4% for Lilly while Novo rose 6%.

reuters

2026-01-13

Jan. 13 Business Watch: Plants Close in Brazil and the UK; Lilly to Pay $1.2 Billion for Ventyx

2026-04-17

Lilly's obesity pill Foundayo gets 1,390 prescriptions in debut week

2026-04-19

Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

2026-04-24

Eli Lilly's Obesity Pill Records Modest Second Week as Battle with Novo Nordisk Intensifies

2026-04-30

S&P 500, Nasdaq On Course for Best Month Since 2020 Despite Middle East Risks